LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants

被引：7

作者：

Westendorf, Kathryn ^{[1
]}

Zentelis, Stefanie ^{[1
]}

Wang, Lingshu ^{[2
]}

Foster, Denisa ^{[3
]}

Vaillancourt, Peter ^{[3
]}

Wiggin, Matthew ^{[1
]}

Lovett, Erica ^{[1
]}

van der Lee, Robin ^{[1
]}

Hendle, Joerg ^{[3
]}

Pustilnik, Anna ^{[3
]}

Sauder, J. Michael ^{[3
]}

Kraft, Lucas ^{[1
]}

Hwang, Yuri ^{[1
]}

Siegel, Robert W. ^{[4
]}

Chen, Jinbiao ^{[4
]}

Heinz, Beverly A. ^{[4
]}

Higgs, Richard E. ^{[4
]}

Kallewaard, Nicole L. ^{[4
]}

Jepson, Kevin ^{[1
]}

Goya, Rodrigo ^{[1
]}

Smith, Maia A. ^{[1
]}

Collins, David W. ^{[1
]}

Pellacani, Davide ^{[1
]}

Xiang, Ping ^{[1
]}

de Puyraimond, Valentine ^{[1
]}

Ricicova, Marketa ^{[1
]}

Devorkin, Lindsay ^{[1
]}

Pritchard, Caitlin ^{[1
]}

O'Neill, Aoise ^{[1
]}

Dalal, Kush ^{[1
]}

Panwar, Pankaj ^{[1
]}

Dhupar, Harveer ^{[1
]}

Garces, Fabian A. ^{[1
]}

Cohen, Courtney A. ^{[5
]}

Dye, John M. ^{[5
]}

Huie, Kathleen E. ^{[5
]}

V. Badger, Catherine ^{[5
]}

Kobasa, Darwyn ^{[6
,7
]}

Audet, Jonathan ^{[6
,7
]}

Freitas, Joshua J. ^{[3
]}

Hassanali, Saleema ^{[3
]}

Hughes, Ina ^{[3
]}

Munoz, Luis ^{[3
]}

Palma, Holly C. ^{[3
]}

Ramamurthy, Bharathi ^{[3
]}

Cross, Robert W. ^{[7
,8
,9
]}

Geisbert, Thomas W. ^{[7
,8
,9
]}

Menachery, Vineet ^{[8
,9
]}

Lokugamage, Kumari ^{[8
,9
]}

Borisevich, Viktoriya ^{[8
]}

机构：

[1] AbCellera Biol Inc, Vancouver, BC V5Y 0A1, Canada

[2] NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA

[3] Eli Lilly & Co, Lilly Biotechnol Ctr, San Diego, CA 92121 USA

[4] Eli Lilly & Co, Indianapolis, IN 46285 USA

[5] US Army Med Res Inst Infect Dis USAMRIID, Frederick, MD 21702 USA

[6] Publ Hlth Agcy Canada, Natl Microbiol Lab, Winnipeg, MB R3E 3L5, Canada

[7] Univ Manitoba, Winnipeg, MB R3T 2N2, Canada

[8] Univ Texas Med Branch, Galveston Natl Lab, Galveston, TX 77555 USA

[9] Univ Texas Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA

来源：

CELL REPORTS | 2022年 / 39卷 / 07期

基金：

欧盟地平线“2020”;

关键词：

VALIDATION; IMMUNITY;

D O I：

10.1016/j.celrep.2022.110812

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing monoclonal antibodies (mAbs) can reduce the risk of hospitalization from coronavirus disease 2019 (COVID-19) when administered early. However, SARS-CoV-2 variants of concern (VOCs) have negatively affected therapeutic use of some authorized mAbs. Using a high-throughput B cell screening pipeline, we isolated LY-CoV1404 (bebtelovimab), a highly potent SARS-CoV-2 spike glycoprotein receptor binding domain (RBD)-specific antibody. LYCoV1404 potently neutralizes authentic SARS-CoV-2, B.1.1.7, B.1.351, and B.1.617.2. In pseudovirus neutralization studies, LY-CoV1404 potently neutralizes variants, including B.1.1.7, B.1.351, B.1.617.2, B.1.427/ B.1.429, P.1, B.1.526, B.1.1.529, and the BA.2 subvariant. Structural analysis reveals that the contact residues of the LY-CoV1404 epitope are highly conserved, except for N439 and N501. The binding and neutralizing activity of LY-CoV1404 is unaffected by the most common mutations at these positions (N439K and N501Y). The broad and potent neutralization activity and the relatively conserved epitope suggest that LY-CoV1404 has the potential to be an effective therapeutic agent to treat all known variants.

引用

页数：26

共 50 条

[31] An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants
Chi, Xiaojing
Zhang, Xinhui
Pan, Shengnan
Yu, Yanying
Shi, Yujin
Lin, Tianli
Duan, Huarui
Liu, Xiuying
Chen, Wenfang
Yang, Xuehua
Chen, Lan
Dong, Xiaoqian
Ren, Lili
Ding, Qiang
Wang, Jianwei
Yang, Wei
SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2022, 7 (01)
[32] Investigation of SARS-CoV-2 IgG Binding Capability to Variants of the SARS-CoV-2 Virus
Johnson, Lucy
De Gascun, Cillian F.
Hassan, Jaythoon
VIRAL IMMUNOLOGY, 2024, 37 (08) : 404 - 410
[33] Polyvalent Nano-Lectin Potently Neutralizes SARS-CoV-2 by Targeting Glycans on the Viral Spike Protein
Budhadev, Darshita
Hooper, James
Rocha, Cheila
Nehlmeier, Inga
Kempf, Amy Madeleine
Hoffmann, Markus
Krueger, Nadine
Zhou, Dejian
Pohlmann, Stefan
Guo, Yuan
JACS AU, 2023, 3 (06): : 1755 - 1766
[34] SARS-CoV-2 Reinfection With Different SARS-CoV-2 Variants in Children, Ohio, United States
Wang, Huanyu
Wright, Tori
Everhart, Kathy
Oyeniran, Sophonie J.
Mejias, Asuncion
Leber, Amy L.
JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY, 2023, 12 (04) : 198 - 204
[35] The effect of different SARS-CoV-2 variants
Hsu, Chi-Kuei
Lai, Chih-Cheng
ALZHEIMERS & DEMENTIA, 2023, 19 (01) : 369 - 369
[36] The emerging SARS-CoV-2 variants of concern
Sanyaolu, Adekunle
Okorie, Chuku
Marinkovic, Aleksandra
Haider, Nafees
Abbasi, Abu Fahad
Jaferi, Urooj
Prakash, Stephanie
Balendra, Vyshnavy
THERAPEUTIC ADVANCES IN INFECTIOUS DISEASE, 2021, 8
[37] The origin of SARS-CoV-2 variants of concern
Burki, Talha
LANCET INFECTIOUS DISEASES, 2022, 22 (02): : 174 - 175
[38] Antibody vanquishes SARS-CoV-2 variants
Kingwell, Katie
NATURE REVIEWS DRUG DISCOVERY, 2024, 23 (12) : 895 - 895
[39] The Evolution and Biology of SARS-CoV-2 Variants
Telenti, Amalio
Hodcroft, Emma B.
Robertson, David L.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2022, 12 (05):
[40] SARS-CoV-2 variants of concern: a review
Sarkar, Malay
Madabhavi, Irappa
MONALDI ARCHIVES FOR CHEST DISEASE, 2023, 93 (03)

← 1 2 3 4 5 →